BTIG Research has recently initiated Zoetis Inc (ZTS) stock to Buy rating, as announced on July 25, 2024, according to Finviz. Earlier, on January 12, 2024, Stifel had reiterated the stock to Buy, setting a price target of $215 for ZTS stock. Jefferies also resumed Buy rating with a price target of $230. Additionally, Exane BNP Paribas initiated Outperform rating on December 7, 2023, with a target price of $237. HSBC Securities analysts, in their report published on September 6, 2023, also initiated Buy rating and set a price target of $230 for Zoetis Inc’s stock. Analyst ratings are significant because they provide insights into stock performance expectations, influencing investor decisions and market sentiment.
Sponsored
Zoetis Inc (ZTS) Stock Trading Recap
On Monday, Zoetis Inc (ZTS) stock saw a decline, ending the day at $176.15 which represents a decrease of $-0.67 or -0.38% from the prior close of $176.82. The stock opened at $176.98 and touched a low of $175 during the day, reaching a high of $178.38. The volume of shares traded was 3.21 million exceeding the average volume of 1.93 million.
ZTS Stock Performance and Moving Averages
In recent trading, Zoetis Inc (ZTS) stock price has shown some volatility, fluctuating 0.55% over the last five trades and -7.33% over the past 30 trades. This represents a notable shift from earlier in the year. Over the last six months, the stock has risen by 4.91%, and it has plunged by -6.49% in the previous three months. Currently, ZTS is trading at -3.64%, -6.30%, and -1.57% relative to its 20-Day, 50-Day, and 200-Day Simple Moving Averages, respectively.
As of the latest trading close, ZTS, a Healthcare sector stock, is trading -12.76% below its 52-week high but remains 21.65% above its 52-week low. The Average True Range (ATR) (14 days) of 4.43 highlights the stock’s average volatility, providing insight into how much the price typically fluctuates. This measure is crucial for understanding potential price swings and assessing overall market risk.
Zoetis Inc’s Profitability and Valuation Ratios
Zoetis Inc’s profitability metrics reveal strong financial health. The company currently boasts an operating margin of 36.45% and a profit margin of 26.55%, with a gross margin of 4.91%. The profit margin, also known as the revenue ratio or gross profit ratio, measures how efficiently a company converts sales into net income; higher margins indicate greater profitability.
In terms of valuation, Zoetis Inc’s market capitalization stands at $80.64 billion. Market cap represents the total value of all outstanding shares and is a key indicator of a company’s market value. The stock’s price-to-earnings (P/E) ratio is 33.12, assessing the company’s valuation relative to its earnings. The forward P/E ratio, which uses projected earnings for the next financial year, is 27.6. Additionally, the Price-to-Sales Ratio is 8.81, reflecting the market’s valuation of the company’s sales, while the Price-to-Book Ratio is 15.2, comparing the market value to the company’s book value.
Understanding Insider Trading
Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 0.08% of Zoetis Inc (ZTS)’s shares, while financial institutions hold 96.06%.
Notable insider trades include Lagano Roxanne, Executive Vice President at Zoetis Inc (ZTS), who sold 923 shares on Apr 18 ’24, at $151.17 each, totaling $0.14 million. On Mar 18 ’24, Lagano Roxanne, Executive Vice President, sold 923 shares for $173.33 each, amounting to $0.16 million. Additionally, on Mar 11 ’24, Reed Willie M sold 1370 shares at $182.68 each, generating $0.25 million.
